AstraZeneca’s Bestselling Drug May Get Patent Boost With Omthera Deal, Optimer Deal Possible

Compiled by Sam Fazeli, Director Bloomberg Industries Europe and Asthika Goonewardene, Pharmaceuticals Equity Research Analyst

AstraZeneca’s bid to buy Omthera is driven by Epanova, an experimental treatment for patients with high levels of triglycerides that could be combined with the large pharma company’s best-selling medicine Crestor in an effort to stave off generic competition.

 

Read more>>>>

Bloomberg BRIEF Newsletters